


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Serial No.: 09/079,785

Filed: May 15, 1998

For: CD30 LIGAND



Docket No.: 2804-H

Group Art Unit: 1646

Examiner: L. Spector

STATEMENT UNDER 37 CFR 1.821(e)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In the present application, Applicants request use of the computer readable Sequence Listing submitted on April 12, 1994, in the following application of the present Applicants:

Serial no: 08/225,989
Filed: April 12, 1994
Title: NOVEL CYTOKINE THAT BINDS CD30

The computer readable Sequence Listing filed on April 12, 1994 is compliant with the rules relating to Sequence Listings. The paper copy of the Sequence Listing of the present application (found on pages 48-70 of the specification) is identical to the computer readable copy of the Sequence Listing filed on April 12, 1994, in application serial no. 08/225,989. Thus, no computer readable form of the Sequence Listing needs to be submitted with the present application, because such CRF would be identical to the Sequence Listing filed on April 12, 1994, in application serial no. 08/225,989.

Immunex Corporation
51 University Street
Seattle, Washington 98101
(206) 587-0430

Respectfully submitted,

Kathryn A. Anderson
Registration No. 32,172

RECEIVED
JUL 23 1999
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date:

July 15, 1999

Signed: